Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Absci Co. stock logo
ABSI
Absci
$4.51
-5.5%
$5.19
$1.11
$6.72
$508.66M2.361.54 million shs1.62 million shs
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
$3.68
-2.6%
$4.89
$3.60
$10.45
$302.17M0.561.44 million shs1.36 million shs
Inotiv, Inc. stock logo
NOTV
Inotiv
$4.42
+2.3%
$7.58
$1.61
$11.42
$113.99M3.16416,849 shs563,692 shs
National Research Co. stock logo
NRC
National Research
$33.69
-1.0%
$38.46
$32.08
$47.25
$811.77M0.4247,859 shs39,683 shs
Zymergen Inc. stock logo
ZY
Zymergen
$2.43
$2.52
$1.10
$12.42
$253.58M1.691.23 million shs85 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Absci Co. stock logo
ABSI
Absci
-5.45%-16.94%-8.89%+23.56%+166.86%
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
-2.65%-13.00%-21.03%-44.24%-54.17%
Inotiv, Inc. stock logo
NOTV
Inotiv
+2.31%-21.49%-58.46%+27.38%-23.40%
National Research Co. stock logo
NRC
National Research
-1.00%-1.55%-15.73%-15.65%-25.03%
Zymergen Inc. stock logo
ZY
Zymergen
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Absci Co. stock logo
ABSI
Absci
2.3416 of 5 stars
3.52.00.00.01.83.30.6
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
3.3676 of 5 stars
3.50.00.04.72.81.70.0
Inotiv, Inc. stock logo
NOTV
Inotiv
3.0196 of 5 stars
3.55.00.00.00.60.02.5
National Research Co. stock logo
NRC
National Research
0.6104 of 5 stars
0.03.01.70.01.10.81.3
Zymergen Inc. stock logo
ZY
Zymergen
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Absci Co. stock logo
ABSI
Absci
3.00
Buy$9.25105.10% Upside
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
3.00
Buy$40.00986.96% Upside
Inotiv, Inc. stock logo
NOTV
Inotiv
3.00
Buy$15.17243.14% Upside
National Research Co. stock logo
NRC
National Research
N/AN/AN/AN/A
Zymergen Inc. stock logo
ZY
Zymergen
N/AN/AN/AN/A

Current Analyst Ratings

Latest ABSI, ZY, NRC, NOTV, and AVXL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/26/2024
Absci Co. stock logo
ABSI
Absci
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
3/25/2024
Absci Co. stock logo
ABSI
Absci
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$13.00
3/22/2024
Absci Co. stock logo
ABSI
Absci
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
3/14/2024
Absci Co. stock logo
ABSI
Absci
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$13.00
3/6/2024
Absci Co. stock logo
ABSI
Absci
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
3/4/2024
Absci Co. stock logo
ABSI
Absci
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$5.00 ➝ $8.00
2/9/2024
Inotiv, Inc. stock logo
NOTV
Inotiv
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$3.00 ➝ $11.50
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Absci Co. stock logo
ABSI
Absci
$5.72M88.96N/AN/A$1.90 per share2.37
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
N/AN/AN/AN/A$1.73 per shareN/A
Inotiv, Inc. stock logo
NOTV
Inotiv
$572.42M0.20$0.44 per share10.00$10.41 per share0.42
National Research Co. stock logo
NRC
National Research
$148.58M5.41$1.51 per share22.35$2.02 per share16.68
Zymergen Inc. stock logo
ZY
Zymergen
$16.74M15.15N/AN/A$3.99 per share0.61

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Absci Co. stock logo
ABSI
Absci
-$110.57M-$1.20N/AN/AN/A-1,933.65%-44.52%-37.35%5/14/2024 (Confirmed)
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
-$47.51M-$0.54N/AN/AN/AN/A-30.32%-27.87%5/14/2024 (Estimated)
Inotiv, Inc. stock logo
NOTV
Inotiv
-$105.14M-$1.30N/A3.45N/A-5.67%-10.99%-3.45%5/9/2024 (Estimated)
National Research Co. stock logo
NRC
National Research
$30.97M$1.2526.95N/A20.84%47.79%24.27%5/7/2024 (Confirmed)
Zymergen Inc. stock logo
ZY
Zymergen
-$361.79M-$3.55N/AN/AN/A-2,508.94%-93.37%-61.14%N/A

Latest ABSI, ZY, NRC, NOTV, and AVXL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2024N/A
Absci Co. stock logo
ABSI
Absci
-$0.19N/A+$0.19N/AN/AN/A  
5/7/2024N/A
National Research Co. stock logo
NRC
National Research
N/AN/AN/AN/AN/AN/A  
3/21/2024Q4 2023
Absci Co. stock logo
ABSI
Absci
-$0.23-$0.25-$0.02-$0.25$1.75 million$0.34 million
2/13/2024Q4 2023
National Research Co. stock logo
NRC
National Research
N/A$0.36+$0.36$0.36N/A$38.00 million
2/7/2024Q1 2024
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
-$0.15-$0.11+$0.04-$0.11N/AN/A
2/7/2024Q1 2024
Inotiv, Inc. stock logo
NOTV
Inotiv
$0.07-$0.60-$0.67-$0.60$136.26 million$135.50 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Absci Co. stock logo
ABSI
Absci
N/AN/AN/AN/AN/A
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
N/AN/AN/AN/AN/A
Inotiv, Inc. stock logo
NOTV
Inotiv
N/AN/AN/AN/AN/A
National Research Co. stock logo
NRC
National Research
$0.481.42%+31.73%38.40%N/A
Zymergen Inc. stock logo
ZY
Zymergen
N/AN/AN/AN/AN/A

Latest ABSI, ZY, NRC, NOTV, and AVXL Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/13/2024
National Research Co. stock logo
NRC
National Research
Quarterly$0.121.2%3/27/20243/29/20244/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Absci Co. stock logo
ABSI
Absci
0.03
4.08
4.08
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
N/A
11.85
11.85
Inotiv, Inc. stock logo
NOTV
Inotiv
1.46
1.74
1.28
National Research Co. stock logo
NRC
National Research
0.60
0.67
0.67
Zymergen Inc. stock logo
ZY
Zymergen
N/A
4.59
4.47

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Absci Co. stock logo
ABSI
Absci
52.05%
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
31.55%
Inotiv, Inc. stock logo
NOTV
Inotiv
18.17%
National Research Co. stock logo
NRC
National Research
47.26%
Zymergen Inc. stock logo
ZY
Zymergen
52.99%

Insider Ownership

CompanyInsider Ownership
Absci Co. stock logo
ABSI
Absci
11.58%
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
11.60%
Inotiv, Inc. stock logo
NOTV
Inotiv
5.80%
National Research Co. stock logo
NRC
National Research
2.00%
Zymergen Inc. stock logo
ZY
Zymergen
11.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Absci Co. stock logo
ABSI
Absci
155112.79 million99.72 millionOptionable
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
4082.11 million72.59 millionOptionable
Inotiv, Inc. stock logo
NOTV
Inotiv
2,05525.79 million24.30 millionOptionable
National Research Co. stock logo
NRC
National Research
43523.85 million23.38 millionOptionable
Zymergen Inc. stock logo
ZY
Zymergen
502104.36 million92.15 millionNot Optionable

ABSI, ZY, NRC, NOTV, and AVXL Headlines

SourceHeadline
Biomanufacturing isn’t cleaning up chemicalsBiomanufacturing isn’t cleaning up chemicals
cen.acs.org - April 19 at 10:55 AM
Method Communications Introduces New Leadership Structure to Accelerate MomentumMethod Communications Introduces New Leadership Structure to Accelerate Momentum
finance.yahoo.com - April 10 at 10:51 AM
Ginkgo loads up CAR assets from Modulus, the latest in a string of dealsGinkgo loads up CAR assets from Modulus, the latest in a string of deals
fiercebiotech.com - April 2 at 8:57 AM
Molecular Robotics Market Share Analysis, Industry Trends & Statistics and 10 Year Growth Forecasts 2019-2029Molecular Robotics Market Share Analysis, Industry Trends & Statistics and 10 Year Growth Forecasts 2019-2029
tmcnet.com - March 21 at 5:22 PM
GM puts 2 newcomers in pivotal rolesGM puts 2 newcomers in pivotal roles
autonews.com - March 15 at 1:53 PM
Transportation Transitions: Transervice, Fultra, and GM name new leadershipTransportation Transitions: Transervice, Fultra, and GM name new leadership
fleetowner.com - March 15 at 8:52 AM
Biotech Industry Bankruptcy Cases: Zymergen and HumanigenBiotech Industry Bankruptcy Cases: Zymergen and Humanigen
law.com - March 14 at 1:41 PM
GM EVP of global manufacturing and sustainability Gerald Johnson to retire after 44 YearsGM EVP of global manufacturing and sustainability Gerald Johnson to retire after 44 Years
auto.economictimes.indiatimes.com - March 14 at 2:18 AM
GM Appoints Former Tesla and Google Executive to Succeed Retiring Head of ManufacturingGM Appoints Former Tesla and Google Executive to Succeed Retiring Head of Manufacturing
msn.com - March 13 at 8:08 PM
GM Taps Former Tesla Gigafactory Head To Lead ManufacturingGM Taps Former Tesla Gigafactory Head To Lead Manufacturing
marketwatch.com - March 13 at 10:08 AM
GM announces a management shakeup as it loses 2 key executivesGM announces a management shakeup as it loses 2 key executives
freep.com - March 12 at 6:06 PM
GM hires ex-Tesla, Google exec to replace retiring head of manufacturingGM hires ex-Tesla, Google exec to replace retiring head of manufacturing
nbcnewyork.com - March 12 at 6:06 PM
Q4 2023 Ginkgo Bioworks Holdings Inc Earnings CallQ4 2023 Ginkgo Bioworks Holdings Inc Earnings Call
finance.yahoo.com - March 1 at 2:42 PM
Project Izanagi: Masayoshi Son plans $100bn AI chip ventureProject Izanagi: Masayoshi Son plans $100bn AI chip venture
datacenterdynamics.com - February 18 at 10:15 AM
MATTERWORKS ANNOUNCES BOARD UPDATESMATTERWORKS ANNOUNCES BOARD UPDATES
finance.yahoo.com - February 13 at 2:16 AM
SmartLabs gets $48M investment; CEO says we’re not doneSmartLabs gets $48M investment; CEO says 'we’re not done'
bizjournals.com - January 19 at 9:53 AM
SmartLabs Announces Biopharma Veteran Brian Taylor as New Interim CEOSmartLabs Announces Biopharma Veteran Brian Taylor as New Interim CEO
finance.yahoo.com - January 11 at 7:19 AM
Adam D’AugelliAdam D’Augelli
zonebourse.com - December 28 at 8:17 PM
Zymergen Gets OK For Asset Sales : Dramatic Bankruptcy BattleZymergen Gets OK For Asset Sales : Dramatic Bankruptcy Battle
usaherald.com - December 19 at 6:56 PM
Ginkgo Bioworks Holdings Inc (DNA) Reports Q3 2023 Financial ResultsGinkgo Bioworks Holdings Inc (DNA) Reports Q3 2023 Financial Results
finance.yahoo.com - November 8 at 7:28 PM
Tech and biotech firms slash hundreds of Bay Area jobs as layoffs widenTech and biotech firms slash hundreds of Bay Area jobs as layoffs widen
msn.com - November 8 at 7:28 PM
Ginkgo Bioworks Holdings Q3 2023 Earnings PreviewGinkgo Bioworks Holdings Q3 2023 Earnings Preview
msn.com - November 7 at 2:39 PM
Gingko Bioworks, Penn State partner on wildlife biothreat researchGingko Bioworks, Penn State partner on wildlife biothreat research
msn.com - October 24 at 8:19 PM
Ginkgo Bioworks and Zymergen: A tale of two IPOs ends in bankruptcyGinkgo Bioworks and Zymergen: A tale of two IPOs ends in bankruptcy
msn.com - October 4 at 5:34 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Absci logo

Absci

NASDAQ:ABSI
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Anavex Life Sciences logo

Anavex Life Sciences

NASDAQ:AVXL
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Inotiv logo

Inotiv

NASDAQ:NOTV
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
National Research logo

National Research

NASDAQ:NRC
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.
Zymergen logo

Zymergen

NASDAQ:ZY
Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California. As of October 19, 2022, Zymergen Inc. operates as a subsidiary of Ginkgo Bioworks Holdings, Inc.